Genomic Analysis of Circulating Tumor DNA Using a Melanoma-Specific UltraSEEK Oncogene Panel.

07:00 EST 4th February 2019 | BioPortfolio

Summary of "Genomic Analysis of Circulating Tumor DNA Using a Melanoma-Specific UltraSEEK Oncogene Panel."

The analysis of circulating tumor DNA (ctDNA) provides a minimally-invasive molecular interrogation that has the potential to guide treatment selection and disease monitoring. Here, we evaluated a custom UltraSEEK melanoma panel for the MassARRAY system, probing for 61 mutations over 13 genes. The analytical sensitivity and clinical accuracy of the UltraSEEK melanoma panel was compared to droplet digital PCR. The blinded analysis of 68 mutations detected in 48 plasma samples from stage IV melanoma patients revealed a concordance of 88% between the two platforms. Further comparison of both methods for the detection of BRAF V600E mutations in 77 plasma samples demonstrated a Cohen's κ of 0.826 (BCa 95% CI 0.669 to 0.946). Our results indicate that the UltraSEEK melanoma panel is as sensitive as ddPCR for the detection of ctDNA in this cohort of patients but highlight the need for detected variants to be confirmed orthogonally to mitigate any false positive results. The MassARRAY system enables rapid and sensitive genotyping for the detection of multiple melanoma-associated mutations in plasma.


Journal Details

This article was published in the following journal.

Name: The Journal of molecular diagnostics : JMD
ISSN: 1943-7811


DeepDyve research library

PubMed Articles [29135 Associated PubMed Articles listed on BioPortfolio]

Locus-specific concordance of genomic alterations between tissue and plasma circulating tumor DNA (ctDNA) in metastatic melanoma.

Circulating tumor DNA (ctDNA) may serve as a surrogate to tissue biopsy for non-invasive identification of mutations across multiple genetic loci and for disease monitoring in melanoma. In this study,...

Immunomagnetic isolation of circulating melanoma cells and detection of PD-L1 status.

Personalised medicine targeted to specific biomarkers such as BRAF and c-Kit has radically improved the success of melanoma therapy. More recently, further advances have been made using therapies targ...

Circulating tumor DNA in advanced prostate cancer: transitioning from discovery to a clinically implemented test.

The genomic landscape of metastatic castration-resistant prostate cancer (mCRPC) differs from that of the primary tumor and is dynamic during tumor progression. The real-time and repeated characteriza...

Hybrid capture-based genomic profiling of circulating tumor DNA from patients with advanced non-small cell lung cancer.

Genomic profiling informs selection of matched targeted therapies as part of routine clinical care in non-small cell lung cancer (NSCLC). Tissue biopsy is the gold standard; however, genomic profiling...

Clonal heterogeneity of melanoma in a paradigmatic case study: future prospects for circulating melanoma cells.

The management of metastatic melanoma is a difficult matter. Nevertheless, the advent of target therapy has significantly improved patient outcome, provided that tumor molecular characteristics become...

Clinical Trials [11527 Associated Clinical Trials listed on BioPortfolio]

Bio-marker Analysis Using Circulating Tumor Cells in Patients With Melanoma

This research trial studies the levels of a type of biomarker, circulating tumor cells (CTCs), in the blood of patients with stage I-IV melanoma. A biomarker is a biological molecule found...

CAcTUS - Circulating Tumour DNA Guided Switch

The stay aims to determine whether switching from targeted therapy to immunotherapy based on a decrease in levels of circulating tumour DNA in the blood, will improve the outcome in melano...

Evaluation Interest of the Circulating Tumor DNA Dosage in Patient With Hepatic Metastatic Uveal Melanoma Candidate to Complete Resection (ct DNA R0)

Prospective, open labelled, monocentric trial to evaluation of the circulating tumor DNA rate in the blood, before and after curative resection of hepatic metastasis of uveal melanoma (HMU...

Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma

This study intends to analyze the expression of specific sets of markers in tumor samples and in serum from patients with Non-Small Cell lung Cancer (NSCLC) or Stage III or IV melanoma. Th...

Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well imatinib mesylate...

Medical and Biotech [MESH] Definitions

A method for analyzing and mapping differences in the copy number of specific genes or other large sequences between two sets of chromosomal DNA. It is used to look for large sequence changes such as deletions, duplications, or amplifications within the genomic DNA of an individual (with a tumor for example) or family members or population or between species.

Experimentally induced tumor that produces MELANIN in animals to provide a model for studying human MELANOMA.

DNA released from tumor cells that is found circulating in PLASMA; SERUM; or other BODY FLUIDS.

Cellular antigens that are specific for MELANOMA cells.

An unpigmented malignant melanoma. It is an anaplastic melanoma consisting of cells derived from melanoblasts but not forming melanin. (Dorland, 27th ed; Stedman, 25th ed)

Quick Search


DeepDyve research library

Relevant Topics

Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...

  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Searches Linking to this Article